Published in Blood on March 16, 2010
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood (2011) 1.92
Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev (2013) 1.88
Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene (2012) 1.85
Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood (2013) 1.73
Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. Genome Res (2014) 1.28
An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep (2013) 1.21
A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods (2013) 1.17
Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci (2010) 1.14
Human induced pluripotent stem cells can reach complete terminal maturation: in vivo and in vitro evidence in the erythropoietic differentiation model. Haematologica (2012) 1.09
Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles. Mol Ther (2012) 1.07
Myc transcription factors: key regulators behind establishment and maintenance of pluripotency. Regen Med (2010) 1.00
Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene (2013) 1.00
Dissecting the role of aberrant DNA methylation in human leukaemia. Nat Commun (2015) 0.93
Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl Res (2010) 0.93
Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia (2013) 0.90
Using induced pluripotent stem cells as a tool for modelling carcinogenesis. World J Stem Cells (2015) 0.88
Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients. Leukemia (2014) 0.88
Induced pluripotent stem cells as a next-generation biomedical interface. Lab Invest (2011) 0.87
Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. Elife (2015) 0.86
Cellular reprogramming and hepatocellular carcinoma development. World J Gastroenterol (2013) 0.86
Induced pluripotent stem cell-related genes influence biological behavior and 5-fluorouracil sensitivity of colorectal cancer cells. J Zhejiang Univ Sci B (2012) 0.85
Induced pluripotent cancer cells: progress and application. J Cancer Res Clin Oncol (2010) 0.85
Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells. Sci Rep (2012) 0.85
Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO J (2015) 0.85
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1. PLoS One (2015) 0.83
Heterogeneity of osteosarcoma cell lines led to variable responses in reprogramming. Int J Med Sci (2014) 0.83
Functional genomics to uncover drug mechanism of action. Nat Chem Biol (2015) 0.82
Differentiation and transdifferentiation potentials of cancer stem cells. Oncotarget (2015) 0.82
Cancer stem cells converted from pluripotent stem cells and the cancerous niche. J Stem Cells Regen Med (2014) 0.82
Applications of iPSCs in Cancer Research. Biomark Insights (2015) 0.81
Generation of induced pluripotent stem cells from mouse cancer cells. Cancer Biother Radiopharm (2012) 0.81
Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation. PLoS One (2013) 0.81
Reprogramming cancer cells to pluripotency: an experimental tool for exploring cancer epigenetics. Epigenetics (2014) 0.79
Induced Pluripotent Stem Cells-A New Foundation in Medicine. J Exp Clin Med (2010) 0.79
Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line. Front Cell Dev Biol (2015) 0.79
Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. Stem Cell Reports (2016) 0.79
Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. Biomed Res Int (2013) 0.78
Human RGM249-derived small RNAs potentially regulate tumor malignancy. Nucleic Acid Ther (2013) 0.78
Parallel reverse genetic screening in mutant human cells using transcriptomics. Mol Syst Biol (2016) 0.78
Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting. Front Pharmacol (2016) 0.78
Induced pluripotent stem cell technology for dissecting the cancer epigenome. Cancer Sci (2015) 0.77
In vitro models of cancer stem cells and clinical applications. BMC Cancer (2016) 0.77
The promise of human induced pluripotent stem cells in dental research. Stem Cells Int (2012) 0.77
microRNA-based cancer cell reprogramming technology. Exp Ther Med (2012) 0.77
Current status in cancer cell reprogramming and its clinical implications. J Cancer Res Clin Oncol (2016) 0.77
Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nat Med (2016) 0.77
Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. Stem Cell Res (2015) 0.77
Generation and characterization of virus-free reprogrammed melanoma cells by the piggyBac transposon. J Cancer Res Clin Oncol (2013) 0.77
Crosstalk between stem cell and cell cycle machineries. Curr Opin Cell Biol (2015) 0.76
Elite model for the generation of induced pluripotent cancer cells (iPCs). PLoS One (2013) 0.76
The crossroads between cancer stem cells and aging. BMC Cancer (2015) 0.76
Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells. Toxicol Sci (2016) 0.76
Echoes of the embryo: using the developmental biology toolkit to study cancer. Dis Model Mech (2016) 0.76
Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells. Leukemia (2016) 0.76
A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors. Cell Reprogram (2014) 0.75
Susceptibility of Human Oral Squamous Cell Carcinoma (OSCC) H103 and H376 cell lines to Retroviral OSKM mediated reprogramming. PeerJ (2017) 0.75
iTRAQ-based quantitative proteomic analysis of Yamanaka factors reprogrammed breast cancer cells. Oncotarget (2017) 0.75
Susceptibility of pancreatic cancer stem cells to reprogramming. Cancer Sci (2015) 0.75
Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies. J Cancer (2016) 0.75
Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells. Cancer Sci (2015) 0.75
Nuclear reprogramming and the cancer genome. Nat Genet (2013) 0.75
Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models. Stem Cells Int (2016) 0.75
Differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor. Cell Death Dis (2015) 0.75
Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. Stem Cell Reports (2017) 0.75
Mesenchymal to Epithelial Transition Induced by Reprogramming Factors Attenuates the Malignancy of Cancer Cells. PLoS One (2016) 0.75
Tumorigenic potential is restored during differentiation in fusion-reprogrammed cancer cells. Cell Death Dis (2016) 0.75
A human haploid gene trap collection to study lncRNAs with unusual RNA biology. RNA Biol (2016) 0.75
Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases. Cells (2017) 0.75
Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9. Mutat Res Rev Mutat Res (2015) 0.75
An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs. Int J Mol Sci (2016) 0.75
Control of Oxidative Stress and Generation of Induced Pluripotent Stem Cell-like Cells by Jun Dimerization Protein 2. Cancers (Basel) (2013) 0.75
Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors. BMC Cancer (2016) 0.75
Induced Pluripotent Stem Cells: Advances in the Quest for Genetic Stability during Reprogramming Process. Int J Mol Sci (2017) 0.75
Next-generation sequencing traces human induced pluripotent stem cell lines clonally generated from heterogeneous cancer tissue. World J Stem Cells (2017) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2007) 21.93
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell (2008) 10.68
c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell (2007) 8.46
Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 6.50
Generation of induced pluripotent stem cells from human blood. Blood (2009) 4.92
Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer (2007) 3.63
Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell (2009) 3.03
Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev (2004) 2.75
Isolation and characterization of a near-haploid human cell line. Exp Cell Res (1999) 1.66
Tissue, cell and stage specificity of (epi)mutations in cancers. Nat Rev Cancer (2005) 1.24
Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia. Cancer Cell (2004) 0.96
Gleevec: prototype or outlier? Sci STKE (2004) 0.89
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 34.93
The impact of microRNAs on protein output. Nature (2008) 32.39
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 24.00
A chromatin landmark and transcription initiation at most promoters in human cells. Cell (2007) 23.41
Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell (2007) 21.58
Direct conversion of fibroblasts to functional neurons by defined factors. Nature (2010) 18.76
Dissecting direct reprogramming through integrative genomic analysis. Nature (2008) 16.47
Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell (2008) 16.38
Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A (2010) 15.13
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 13.02
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science (2007) 12.41
Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol (2009) 12.40
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell (2008) 12.29
Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol (2011) 11.76
Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell (2008) 10.68
Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell (2005) 9.84
A genomic and functional inventory of deubiquitinating enzymes. Cell (2005) 9.36
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet (2007) 9.25
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol (2007) 9.04
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
Direct cell reprogramming is a stochastic process amenable to acceleration. Nature (2009) 8.71
Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature (2008) 8.69
Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res (2005) 8.69
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science (2003) 8.48
c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell (2007) 8.46
YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol (2007) 8.11
One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell (2013) 7.99
A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol (2008) 7.91
Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A (2008) 7.52
Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell (2012) 7.17
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
Induction of human neuronal cells by defined transcription factors. Nature (2011) 6.84
Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis (2006) 6.64
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Chromosomal instability and tumors promoted by DNA hypomethylation. Science (2003) 6.02
Human embryonic stem cells derived by somatic cell nuclear transfer. Cell (2013) 5.91
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
Chromosomal silencing and localization are mediated by different domains of Xist RNA. Nat Genet (2002) 5.51
Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell (2008) 5.40
Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell (2007) 5.29
Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell (2010) 5.13
Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci U S A (2010) 5.00
Haploid genetic screens in human cells identify host factors used by pathogens. Science (2009) 4.91
Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell (2011) 4.85
The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron (2006) 4.74
Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells (2008) 4.67
Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell (2010) 4.59
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell (2011) 4.52
Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A (2005) 4.52
Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep (2003) 4.52
Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A (2008) 4.48
Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell (2008) 4.43
Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat Biotechnol (2008) 4.41
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell (2005) 4.40
Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell (2010) 4.32
Monoclonal mice generated by nuclear transfer from mature B and T donor cells. Nature (2002) 4.16
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell (2009) 3.92
H2AZ is enriched at polycomb complex target genes in ES cells and is necessary for lineage commitment. Cell (2008) 3.90
DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet (2009) 3.73
Towards germline gene therapy of inherited mitochondrial diseases. Nature (2012) 3.73
Nuclear reprogramming and pluripotency. Nature (2006) 3.68
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54
Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc Natl Acad Sci U S A (2012) 3.52
Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res (2013) 3.50
Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell (2009) 3.42
Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell (2013) 3.31
Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell (2011) 3.31